Evidence map›Paper›PMID 36152064›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players.

Michael L Alosco, Yi Su, Thor D Stein, Hillary Protas, Jonathan D Cherry, Charles H Adler, Laura J Balcer, Charles Bernick, Surya Vamsi Pulukuri, Bobak Abdolmohammadi and 18 more

Open access · hybridAbstract readComment
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Molecular neurodegeneration · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 2 countries.

Michael L Alosco *Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8113-8428
Yi Su *Banner Alzheimer's Institute, Arizona State University, and Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
Thor D Stein *Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Hillary ProtasBanner Alzheimer's Institute, Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
Jonathan D CherryBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Charles H AdlerDepartment of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Laura J BalcerDepartments of Neurology, Population Health and Ophthalmology, NYU Grossman School of Medicine, New York, NY, USA.
Charles BernickCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Surya Vamsi PulukuriBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Bobak AbdolmohammadiBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Michael J ColemanPsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Joseph N PalmisanoBiostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, MA, USA.
Yorghos TripodisBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Jesse MezBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Gil D RabinoviciMemory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Kenneth L MarekInstitute for Neurodegenerative Disorders, Invicro, LLC, New Haven, CT, USA.
Thomas G BeachBanner Sun Health Research Institute, Sun City, Arizona, USA.
Keith A JohnsonMassachusetts General Hospital, Boston, MA, USA.
Bertrand Russell HuberBoston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Inga KoertePsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Alexander P LinPsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Sylvain BouixPsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA.
Jeffrey L CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
Martha E ShentonVA Boston Healthcare System, Boston, MA, USA.
Eric M Reiman *Banner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix, AZ, USA.
Ann C McKee *Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
Robert A Stern *Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University School of Medicine, Boston, MA, USA. bobstern@bu.edu.
DIAGNOSE C. T. E. Research Project
Boston University · USBrigham and Women's Hospital · USAlzheimer's Association · USBanner Sun Health Research Institute · USInstitute for Neurodegenerative Disorders · USMayo Clinic in Arizona · USNew York University · USCleveland Clinic · USUniversity of Nevada, Las Vegas · USUniversity of Washington · USTranslational Genomics Research Institute · USUniversity of California, San Francisco · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Mary Sherman Mittelman · 2020 to 2026
$28.4M
RL5: Research Education CoreP30AG072978 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Ann C. McKee · 2021 to 2026
$25.6M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk FactorsU01NS093334 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CUMMINGS, JEFFREY L., REIMAN, ERIC MICHAEL · 2016 to 2022
$17.0M
Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical SyndromesU54NS115266 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2019 to 2023
$10.3M
NVEDARC Clinical CoreP20AG068053 · NIA · CLEVELAND CLINIC FOUNDATION · PI FOX, ROBERT J. · 2020 to 2022
$3.3M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
Sex Differences in Brain Structure and Function After Sports-Related ConcussionR01NS100952 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI KOERTE, INGA KATHARINA · 2017 to 2022
$2.9M
BLRD VA IK2 BX004349NCATS NIH HHS 1UL1TR001430NCATS NIH HHS UL1 TR001430NIA NIH HHS P20 AG068053NIA NIH HHS P20AG068053NIA NIH HHS P30 AG019610NIA NIH HHS P30AG019610NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG072978NIA NIH HHS P30AG072978NIA NIH HHS P30 AG072980NIA NIH HHS P30AG072980NIA NIH HHS R01 AG053798NIA NIH HHS R01AG053798NIA NIH HHS R35 AG071476NIA NIH HHS R35AG71476NIGMS NIH HHS P20 GM109025NIGMS NIH HHS P20GM109025NINDS NIH HHS K23 NS102399NINDS NIH HHS K23NS102399NINDS NIH HHS R01 NS078337NINDS NIH HHS R01NS078337NINDS NIH HHS R01 NS100952NINDS NIH HHS R01NS100952NINDS NIH HHS RF1 NS122854NINDS NIH HHS RF1NS122854NINDS NIH HHS U01 NS093334NINDS NIH HHS U01NS093334NINDS NIH HHS U54 NS115266NINDS NIH HHS U54NS115266
6 · The paper itself

Abstract

purposeFlourine-18-flortaucipir tau positron emission tomography (PET) was developed for the detection for Alzheimer's disease. Human imaging studies have begun to investigate its use in chronic traumatic encephalopathy (CTE). Flortaucipir-PET to autopsy correlation studies in CTE are needed for diagnostic validation. We examined the association between end-of-life flortaucipir PET and postmortem neuropathological measurements of CTE-related tau in six former American football players.

methodsThree former National Football League players and three former college football players who were part of the DIAGNOSE CTE Research Project died and agreed to have their brains donated. The six players had flortaucipir (tau) and florbetapir (amyloid) PET prior to death. All brains from the deceased participants were neuropathologically evaluated for the presence of CTE. On average, the participants were 59.0 (SD = 9.32) years of age at time of PET. PET scans were acquired 20.33 (SD = 13.08) months before their death. Using Spearman correlation analyses, we compared flortaucipir standard uptake value ratios (SUVRs) to digital slide-based AT8 phosphorylated tau (p-tau) density in a priori selected composite cortical, composite limbic, and thalamic regions-of-interest (ROIs).

resultsFour brain donors had autopsy-confirmed CTE, all with high stage disease (n = 3 stage III, n = 1 stage IV). Three of these four met criteria for the clinical syndrome of CTE, known as traumatic encephalopathy syndrome (TES). Two did not have CTE at autopsy and one of these met criteria for TES. Concomitant pathology was only present in one of the non-CTE cases (Lewy body) and one of the CTE cases (motor neuron disease). There was a strong association between flortaucipir SUVRs and p-tau density in the composite cortical (ρ = 0.71) and limbic (ρ = 0.77) ROIs. Although there was a strong association in the thalamic ROI (ρ = 0.83), this is a region with known off-target binding. SUVRs were modest and CTE and non-CTE cases had overlapping SUVRs and discordant p-tau density for some regions.

conclusionsFlortaucipir-PET could be useful for detecting high stage CTE neuropathology, but specificity to CTE p-tau is uncertain. Off-target flortaucipir binding in the hippocampus and thalamus complicates interpretation of these associations. In vivo biomarkers that can detect the specific p-tau of CTE across the disease continuum are needed.

Indexed as

Alzheimer DiseaseBrain Injuries, TraumaticChronic Traumatic EncephalopathyFootballAutopsyBrainCarbolinesDeathHumansPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinestau ProteinsBiomarkersChronic traumatic encephalopathyFlortaucipirFootballNeurodegenerative diseasePositron emission tomography imagingRepetitive head impactsTau

Identifiers

PMID36152064
PMCPMC9816291
OpenAlexW4296970957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.